Document is current
Any future updates will be listed below
-
Authors
Chin, J. F.
Abou Kamar, S.
Motiram, P. A.
Snelder, S. M.
Kardys, I.
Brugts, J. J.
de Boer, R. A.
van Dalen, B. M.
-
Funding
Funding for this research was provided by:
Stichting BeterKeten
Stichting Onderzoek Franciscus
- License Information
-
More Information
Article History
Received: 15 December 2025
Accepted: 1 July 2026
First Online: 21 July 2026
Declarations
Competing interests: The institution of Dr. De Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Dr. de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Dr. de Boer received travel support from Abbott and NovoNordisk. Dr. Kardys received travel reimbursement from Olink and SomaLogic. Dr Brugts reports speaker engagement with Astra Zeneca, Abbott, Bayer, Boehringer, Novartis and Vifor in the past 5 years not related to the current work. The remaining authors report no relationships that could be construed as a conflict of interest. The institution of Dr. Van Dalen received research grants from Biotronik SE & Co. KG, Boehringer Ingelheim, Pfizer, Daiichi Sankyo, Sanofi and Novo Nordisk.
